ArcanaBio
Develops advanced diagnostics systems that enable low cast, rapid and scalable biomonitoring for biosafety and health.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
* | N/A | Early VC | |
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 1254 % | 75 % | 50 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | 55 % | 7 % | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
ArcanaBio is a company that operates in the healthcare technology sector, with a focus on real-time biosurveillance. The company has developed a platform that utilizes biophotonics and artificial intelligence to provide advanced diagnostic systems. This technology is designed for low-cost, rapid, and scalable biomonitoring for health and wellness purposes.
The core of ArcanaBio's offering is a label-free biophotonics platform that enables saliva-based analysis, transforming DNA data into diagnostics. This is delivered through a Software as a Service (SaaS) model, which includes specialized software for the scientific analysis of genetic information. The primary application of this technology is in the workplace, where it serves as a biosurveillance solution to minimize disruptions and promote employee health.
Keywords: biosurveillance, diagnostics, biophotonics, SaaS, saliva-based testing, workplace health, DNA analysis, biomonitoring, healthcare technology, genetic analysis